第六节 结论
食管鳞癌（ESCC）的病例多、预后差、复发率高，且治疗手段有限，亟须更加有效的新型治疗手段。作为免疫治疗的重要手段，CAR-T细胞具有特异性强、杀伤活性高、杀伤潜能强等优势，将有利于改善ESCC治疗。本研究选择了CD276和HER2作为ESCC治疗靶点。实验结果显示，CD276和HER2在ESCC肿瘤组织中的表达水平高，且具有良好互补性，是较好的治疗靶点组合。构建CAR-T细胞后，发现同时靶向2个抗原的CAR-T细胞能够高效杀伤ESCC细胞和PDX肿瘤，并且可克服肿瘤抗原表达异质性。因此，基于CD276和HER2的双靶点CAR-T细胞在未来有望成为食管癌患者治疗的新选择。
参考文献
［1］Lagergren J，Smyth E，Cunningham D，Lagergren P.Oesophageal cancer［J］.Lancet，2017，390 （10110）：2383-2396.
［2］陈万青，孙可欣，郑荣寿，等.2014年中国分地区恶性肿瘤发病和死亡分析［J］.中国肿瘤，2018，27（01）：1-14.
［3］Zeng H，Zheng R，Guo Y，Zhang S，Zou X，Wang N，Zhang L，Tang J，Chen J，Wei K，Huang S，Wang J，Yu L，Zhao D，Song G，Chen J，Shen Y，Yang X，Gu X，Jin F，Li Q，Li Y，Ge H，Zhu F，Dong J，Guo G，Wu M，Du L，Sun X，He Y，Coleman MP，Baade P，Chen W，Yu XQ.Cancer survival in China，2003-2005：a population-based study［J］.Int J Cancer，2015，136（8）：1921-1930.
［4］Sudo K，Xiao L，Wadhwa R，Shiozaki H，Elimova E，Taketa T，Blum MA，Lee JH，Bhutani MS，Weston B，Ross WA，Komaki R，Rice DC，Swisher SG，Hofstetter WL，Maru DM，Skinner HD，Ajani JA.Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer［J］.J Clin Oncol，2014，32（30）：3400-3405.
［5］Song Y，Li L，Ou Y，Gao Z，Li E，Li X，Zhang W，Wang J，Xu L，Zhou Y，Ma X，Liu L，Zhao Z，Huang X，Fan J，Dong L，Chen G，Ma L，Yang J，Chen L，He M，Li M，Zhuang X，Huang K，Qiu K，Yin G，Guo G，Feng Q，Chen P，Wu Z，Wu J，Ma L，Zhao J，Luo L，Fu M，Xu B，Chen B，Li Y，Tong T，Wang M，Liu Z，Lin D，Zhang X，Yang H，Wang J，Zhan Q.Identification of genomic alterations in oesophageal squamous cell cancer［J］.Nature，2014，509（7498）：91-95.
［6］Sadelain M，Riviere I，Riddell S.Therapeutic T cell engineering［J］.Nature，2017，545（7655）：423-431.
［7］Scholler J，Brady TL，Binder-Scholl G，Hwang WT，Plesa G，Hege KM，Vogel AN，Kalos M，Riley JL，Deeks SG，Mitsuyasu RT，Bernstein WB，Aronson NE，Levine BL，Bushman FD，June CH.Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells［J］.Sci Transl Med，2012，4（132）：132，153.
［8］Schuster SJ，Svoboda J，Chong EA，Nasta SD，Mato AR，Anak Ö，Brogdon JL，Pruteanu-Malinici I，Bhoj V，Landsburg D，Wasik M，Levine BL，Lacey SF，Melenhorst JJ，Porter DL，June CH.Chimeric antigen receptor t cells in refractory B-cell lymphomas［J］.N Engl J Med，2017，377（26）：2545-2554.
［9］Maude SL，Laetsch TW，Buechner J，Rives S，Boyer M，Bittencourt H，Bader P，Verneris MR，Stefanski HE，Myers GD，Qayed M，De Moerloose B，Hiramatsu H，Schlis K，Davis KL，Martin PL，Nemecek ER，Yanik GA，Peters C，Baruchel A，Boissel N，Mechinaud F，Balduzzi A，Krueger J，June CH，Levine BL，Wood P，Taran T，Leung M，Mueller KT，Zhang Y，Sen K，Lebwohl D，Pulsipher MA，Grupp SA.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia［J］.N Engl J Med，2018，378（5）：439-448.
［10］Lim WA，June CH.The principles of engineering immune cells to treat cancer［J］.Cell，2017，168（4）：724-740.
［11］Ahmed N，Brawley VS，Hegde M，Robertson C，Ghazi A，Gerken C，Liu E，Dakhova O，Ashoori A，Corder A，Gray T，Wu MF，Liu H，Hicks J，Rainusso N，Dotti G，Mei Z，Grilley B，Gee A，Rooney CM，Brenner MK，Heslop HE，Wels WS，Wang LL，Anderson P，Gottschalk S.Human epidermal growth factor receptor 2 （HER2）-specific chimeric antigen receptormodified T cells for the immunotherapy of HER2-positive sarcoma［J］.J Clin Oncol，2015，33（15）：1688-1696.
［12］Brown CE，Alizadeh D，Starr R，Weng L，Wagner JR，Naranjo A，Ostberg JR，Blanchard MS，Kilpatrick J，Simpson J，Kurien A，Priceman SJ，Wang X，Harshbarger TL，D'Apuzzo M，Ressler JA，Jensen MC，Barish ME，Chen M，Portnow J，Forman SJ，Badie B.Regression of glioblastoma after chimeric antigen receptor T-cell therapy［J］.N Engl J Med，2016，375（26）：2561-2569.
［13］Hegde M，Corder A，Chow KK，Mukherjee M，Ashoori A，Kew Y，Zhang YJ，Baskin DS，Merchant FA，Brawley VS，Byrd TT，Krebs S，Wu MF，Liu H，Heslop HE，Gottschalk S，Yvon E，Ahmed N.Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma［J］.Mol Ther，2013，21（11）：2087-2101.
［14］Pellegatta S，Savoldo B，Di Ianni N，Corbetta C，Chen Y，Patané M，Sun C，Pollo B，Ferrone S，DiMeco F，Finocchiaro G，Dotti G.Constitutive and TNFalpha-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres：Implications for CAR-T cell therapy［J］.Sci Transl Med，2018，10（430）：eaao2731.
［15］Fry TJ，Shah NN，Orentas RJ，Stetler-Stevenson M，Yuan CM，Ramakrishna S，Wolters P，Martin S，Delbrook C，Yates B，Shalabi H，Fountaine TJ，Shern JF，Majzner RG，Stroncek DF，Sabatino M，Feng Y，Dimitrov DS，Zhang L，Nguyen S，Qin H，Dropulic B，Lee DW，Mackall CL.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy［J］.Nat Med，2018，24（1）：20-28.(https://www.daowen.com)
［16］Shalabi H，Kraft IL，Wang HW，Yuan CM，Yates B，Delbrook C，Zimbelman JD，Giller R，Stetler-Stevenson M，Jaffe ES，Lee DW，Shern JF，Fry TJ，Shah NN.Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma［J］.Haematologica，2018，103（5）：e215-e218.
［17］Riaz N，Havel JJ，Makarov V，Desrichard A，Urba WJ，Sims JS，Hodi FS，Martín-Algarra S，Mandal R，Sharfman WH，Bhatia S，Hwu WJ，Gajewski TF，Slingluff CL Jr，Chowell D，Kendall SM，Chang H，Shah R，Kuo F，Morris LGT，Sidhom JW，Schneck JP，Horak CE，Weinhold N，Chan TA.Tumor and microenvironment evolution during immunotherapy with Nivolumab［J］.Cell，2017，171（4）：934-949 .e16.
［18］Hegde M，Mukherjee M，Grada Z，Pignata A，Landi D，Navai SA，Wakefield A，Fousek K，Bielamowicz K，Chow KK，Brawley VS，Byrd TT，Krebs S，Gottschalk S，Wels WS，Baker ML，Dotti G，Mamonkin M，Brenner MK，Orange JS，Ahmed N.Tandem CAR T cells targeting HER2 and IL13Ralphα2 mitigate tumor antigen escape［J］.J Clin Invest，2016，126（8）：3036-3052.
［19］O'Rourke DM，Nasrallah MP，Desai A，Melenhorst JJ，Mansfield K，Morrissette JJD，Martinez-Lage M，Brem S，Maloney E，Shen A，Isaacs R，Mohan S，Plesa G，Lacey SF，Navenot JM，Zheng Z，Levine BL，Okada H，June CH，Brogdon JL，Maus MV.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma［J］.Sci Transl Med，2017，9（399）：eaaa0984.
［20］Ruella M，Barrett DM，Kenderian SS，Shestova O，Hofmann TJ，Perazzelli J，Klichinsky M，Aikawa V，Nazimuddin F，Kozlowski M，Scholler J，Lacey SF，Melenhorst JJ，Morrissette JJ，Christian DA，Hunter CA，Kalos M，Porter DL，June CH，Grupp SA，Gill S.Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies［J］.J Clin Invest，2016，126（10）：3814-3826.
［21］Mimura K，Kono K，Maruyama T，Watanabe M，Izawa S，Shiba S，Mizukami Y，Kawaguchi Y，Inoue M，Kono T，Choudhury A，Kiessling R，Fujii H.Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines［J］.Int J Cancer，2011，129（10）：2408-2416.
［22］Seaman S，Zhu Z，Saha S，Zhang XM，Yang MY，Hilton MB，Morris K，Szot C，Morris H，Swing DA，Tessarollo L，Smith SW，Degrado S，Borkin D，Jain N，Scheiermann J，Feng Y，Wang Y，Li J，Welsch D，DeCrescenzo G，Chaudhary A，Zudaire E，Klarmann KD，Keller JR，Dimitrov DS，St Croix B.Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature［J］.Cancer Cell，2017，31（4）：501-515，e508.
［23］Picarda E，Ohaegbulam KC，Zang X.Molecular Pathways：Targeting B7-H3（CD276） for human cancer immunotherapy［J］.Clin Cancer Res，2016，22（14）：3425-3431.
［24］Loo D，Alderson RF，Chen FZ，Huang L，Zhang W，Gorlatov S，Burke S，Ciccarone V，Li H，Yang Y，Son T，Chen Y，Easton AN，Li JC，Rillema JR，Licea M，Fieger C，Liang TW，Mather JP，Koenig S，Stewart SJ，Johnson S，Bonvini E，Moore PA.Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity［J］.Clin Cancer Res，2012，18（14）：3834-3845.
［25］Powderly J，Cote G，Flaherty K，Szmulewitz RZ，Ribas A，Weber J，Loo D，Baughman J，Chen F，Moore P，Bonvini E，Vasselli J，Wigginton J，Cohen R，Burris H，Chmielowski B.Interim results of an ongoing Phase I，dose escalation study of MGA271 （Fcoptimized humanized anti-B7-H3 monoclonal antibody） in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3［J］.J Immuno Ther Cancer，2015，3（Suppl 2）：08.
［26］Ahmed N，Brawley V，Hegde M，Bielamowicz K，Kalra M，Landi D，Robertson C，Gray TL，Diouf O，Wakefield A，Ghazi A，Gerken C，Yi Z，Ashoori A，Wu MF，Liu H，Rooney C，Dotti G，Gee A，Su J，Kew Y，Baskin D，Zhang YJ，New P，Grilley B，Stojakovic M，Hicks J，Powell SZ，Brenner MK，Heslop HE，Grossman R，Wels WS，Gottschalk S.HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma：a phase 1 dose-escalation trial［J］.JAMA oncology，2017，3（8）：1094-1101.
［27］Zah E，Lin MY，Silva-Benedict A，Jensen MC，Chen YY.T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells［J］.Cancer immunol res，2016，4（6）：498-508.
［28］Kawalekar OU，O'Connor RS，Fraietta JA，Guo L，McGettigan SE，Posey AD Jr，Patel PR，Guedan S，Scholler J，Keith B，Snyder NW，Blair IA，Milone MC，June CH.Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells［J］.Immunity，2016，44（2）：380-390.
［29］Long AH，Haso WM，Shern JF，Wanhainen KM，Murgai M，Ingaramo M，Smith JP，Walker AJ，Kohler ME，Venkateshwara VR，Kaplan RN，Patterson GH，Fry TJ，Orentas RJ，Mackall CL.4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors［J］.Nat Med，2015，21（6）：581-590.
［30］Cassidy JW，Caldas C，Bruna A.Maintaining tumor heterogeneity in patient-derived tumor xenografts［J］.Cancer Res，2015，75（15）：2963-2968.
［31］Sheng Y，Liu K，Wu Q，Oi N，Chen H，Reddy K，Jiang Y，Yao K，Li H，Li W，Zhang Y，Saleem M，Ma WY，Bode AM，Dong Z，Dong Z.PPMP，a novel tubulindepolymerizing agent against esophageal cancer in patient-derived tumor xenografts［J］.Oncotarget，2016，7（21）：30977- 30989.
（李 峰）